Form 4: Athira Pharma Director John M. Fluke Jr. Granted 20,900 Stock Options

Athira Pharma, Inc. Director John M. Fluke Jr. was granted 20,900 stock options with an exercise price of $0.3125, vesting based on time or the next annual meeting, as part of the company's outside director compensation policy.

Summary

• John M. Fluke Jr., a Director of Athira Pharma, Inc. (ATHA), acquired 20,900 stock options.
• The transaction date for this acquisition was May 30, 2025.
• Each stock option has an exercise price of $0.3125.
• The options will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.
• The options were granted pursuant to the terms of Athira Pharma's Outside Director Compensation Policy.
• The expiration date for these stock options is May 29, 2035.
• Following this transaction, John M. Fluke Jr. beneficially owns 20,900 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a routine transaction, the grant of stock options to a director aligns their interests with shareholders, which is generally viewed favorably as it incentivizes long-term value creation. It does not indicate any immediate financial distress or significant operational changes, but rather a standard governance practice.

Positives

• The grant of stock options aligns the financial interests of Director John M. Fluke Jr. with those of the shareholders, incentivizing long-term company performance.
• The transaction is part of a pre-existing, disclosed Outside Director Compensation Policy, indicating a structured approach to executive and director remuneration.

Future Outlook

The vesting schedule of the options, tied to either a specific date (May 30, 2026) or the next annual meeting, indicates a future alignment of the director's incentives with the company's long-term performance and shareholder value creation.

Management Comments

• The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

Industry Context

The grant of stock options to an outside director is a common practice in the biotechnology and pharmaceutical industry, as well as across many public sectors, serving to align the interests of board members with those of the company's shareholders. This type of compensation is standard for attracting and retaining experienced board talent.

Comparison to Industry Standards

• The practice of granting stock options as part of an outside director's compensation package is a widely adopted standard across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• This aligns with compensation strategies seen in comparable biotech firms, where equity-based incentives are used to foster long-term commitment and performance alignment from non-executive directors.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as positive for shareholders as it aligns the director's financial incentives with the company's stock performance, potentially leading to better long-term decision-making aimed at increasing shareholder value.

Next Steps

• The stock options will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.
• Upon vesting, the director will have the right to exercise these options to acquire common stock at the specified exercise price before the expiration date of May 29, 2035.

Key Dates

Keywords

Athira Pharma, ATHA, Stock Option, Director Compensation, Insider Transaction, Form 4, Beneficial Ownership, Equity Grant